Advertisement
Screener

GT BIOPHARMA, INC. (GTBP) Share-based Payment Arrangement, Expense

2.8 / 5 stars · 68/120 Roast Me

GT BIOPHARMA, INC. Share-based Payment Arrangement, Expense

GT BIOPHARMA, INC. (GTBP) reported Share-based Payment Arrangement, Expense of $42.00 thousand for the 12-month period ending 2016-12-31, per its 10-K/A filed 2018-02-28.

Discontinued › Expense Statement › Operating Expenses

us-gaap:AllocatedShareBasedCompensationExpense · last filed 2018-02-28

  • GT BIOPHARMA, INC. share-based payment arrangement, expense for the quarter ending 2015-12-31 was -$1.60M, a 1087.04% decline year-over-year.
  • GT BIOPHARMA, INC. share-based payment arrangement, expense for the quarter ending 2015-03-31 was $163.00K.
  • GT BIOPHARMA, INC. share-based payment arrangement, expense for the quarter ending 2014-12-31 was $162.00K, a 78.51% decline year-over-year.
  • GT BIOPHARMA, INC. share-based payment arrangement, expense for the quarter ending 2014-09-30 was $0.00.
  • GT BIOPHARMA, INC. share-based payment arrangement, expense for fiscal 2016 was $42.00K, a 81.00% decline from fiscal 2015.
  • GT BIOPHARMA, INC. share-based payment arrangement, expense for fiscal 2015 was $221.00K, a 36.42% increase from fiscal 2014.
  • GT BIOPHARMA, INC. share-based payment arrangement, expense for fiscal 2014 was $162.00K, a 82.56% decline from fiscal 2013.
  • GT BIOPHARMA, INC. share-based payment arrangement, expense for fiscal 2013 was $929.00K, a 206.60% increase from fiscal 2012.
Period endShare-based Payment Arrangement, Expense 3 monthShare-based Payment Arrangement, Expense 3 month as first filedShare-based Payment Arrangement, Expense 6 monthShare-based Payment Arrangement, Expense 9 monthShare-based Payment Arrangement, Expense 12 monthShare-based Payment Arrangement, Expense 12 month as first filed
2016-12-31$42.00K
10-K/A · filed 2018-02-28
2015-12-31-$1.60M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-02-28
$221.00K
10-K/A · filed 2018-02-28
2015-09-30$1.82M
10-Q · filed 2015-11-13
2015-03-31$163.00K
10-Q · filed 2015-05-14
$325.00K
derived: sum of 2 quarters · filed 2018-02-28
$325.00K
derived: sum of 3 quarters · filed 2018-02-28
$325.00K
derived: sum of 4 quarters · filed 2018-02-28
2014-12-31$162.00K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-02-28
$162.00K
derived: sum of 2 quarters · filed 2018-02-28
$162.00K
derived: sum of 3 quarters · filed 2018-02-28
$162.00K
10-K/A · filed 2018-02-28
2014-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13
$0.00
derived: sum of 2 quarters · filed 2015-11-13
$0.00
10-Q · filed 2015-11-13
$754.00K
derived: sum of 4 quarters · filed 2015-11-13
2014-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-01-08
$0.00
10-Q · filed 2015-01-08
$754.00K
derived: sum of 3 quarters · filed 2015-05-14
$754.00K
derived: sum of 4 quarters · filed 2015-05-14
2014-03-31$0.00
10-Q · filed 2015-05-14
$754.00K
derived: sum of 2 quarters · filed 2015-05-14
$754.00K
derived: sum of 3 quarters · filed 2015-05-14
$754.00K
derived: sum of 4 quarters · filed 2015-05-14
2013-12-31$754.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31
$754.00K
derived: sum of 2 quarters · filed 2015-03-31
$754.00K
derived: sum of 3 quarters · filed 2015-03-31
$929.00K
10-K · filed 2015-03-31
2013-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-01-08
$0.00
derived: sum of 2 quarters · filed 2015-01-08
$175.00K
10-Q · filed 2015-01-08
-$221.00K
derived: sum of 4 quarters · filed 2015-01-08
2013-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-01-08
$175.00K
10-Q · filed 2015-01-08
-$221.00K
derived: sum of 3 quarters · filed 2015-01-08
$57.00K
derived: sum of 4 quarters · filed 2015-01-08
2013-03-31$175.00K
10-Q · filed 2015-01-08
$176.00K
10-Q · filed 2014-12-10
-$221.00K
derived: sum of 2 quarters · filed 2015-01-08
$57.00K
derived: sum of 3 quarters · filed 2015-01-08
$335.00K
derived: sum of 4 quarters · filed 2015-01-08
2012-12-31-$396.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-01-08
-$118.00K
derived: sum of 2 quarters · filed 2015-01-08
$160.00K
derived: sum of 3 quarters · filed 2015-01-08
$303.00K
10-K · filed 2015-01-08
$929.00K
10-K · filed 2014-11-18
2012-09-30$278.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-12-17
$556.00K
derived: sum of 2 quarters · filed 2014-12-17
$699.00K
10-Q · filed 2014-12-17
$695.00K
derived: sum of 4 quarters · filed 2014-12-17
2012-06-30$278.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-12
$421.00K
10-Q · filed 2014-12-12
$417.00K
derived: sum of 3 quarters · filed 2014-12-12
2012-03-31$143.00K
10-Q · filed 2014-12-10
$139.00K
derived: sum of 2 quarters · filed 2014-12-10
2011-12-31-$4.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-18
$303.00K
10-K · filed 2014-11-18
2011-09-30$307.00K
10-Q · filed 2012-11-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
Evommune, Inc. (EVMN)United States$0.320B-5.10
STANDARD BIOTOOLS INC. (LAB)United States$0.297B3.80
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88